Lun - Ven 8:00 - 17:00
[51] The use of PDE5 inhibitors for the treatment of premature ejaculation
Any serious primary medical condition (eg, angina) should be treated; for the purposes of the following discussion, the patient is assumed to be healthy, and premature ejaculation is assumed to be his only problem. In addition, any accompanying erection problem (eg, erectile dysfunction [ED]) should be treated; various methods are available, and excellent success can be expected. Accordingly, treatment of concomitant ED is mentioned only in passing. To achieve the best outcome, the female partner should be included as fully as possible in the treatment and counseling sessions. Pharmacologic therapy may include selective serotonin reuptake inhibitors (SSRIs) or topical desensitizing agents.
Outpatient care can be scheduled as appropriate for the clinical circumstances. To date, no drug has been specifically approved by the US Food and Drug Administration (FDA) for the treatment of premature ejaculation. However, numerous studies have shown that selective serotonin reuptake inhibitors (SSRIs) and drugs with SSRI-like side effects are safe and effective to treat this condition, and many physicians use these agents for this purpose. Topical desensitizing therapy with local anesthetic agents can also be useful in some men with premature ejaculation. Premature ejaculation that relates to erectile dysfunction may resolve if the erectile dysfunction is treated successfully.
If a patient has depression-related erectile dysfunction but not premature ejaculation, a drug with minimal adverse sexual effects might be considered so as to avoid causing delayed ejaculation or even anorgasmia. [24] However, if the patient has premature ejaculation, erectile dysfunction, and depression, an antidepressant with SSRI side effects has the added benefit of possibly alleviating the premature ejaculation. In Korea and other areas of the Far East, SS (Super Secret) cream (a combination of 9 ingredients, mainly herbal) has been shown to desensitize the penis, decrease the vibratory threshold, and help men with premature ejaculation to delay their ejaculatory response significantly. [26, 27] This preparation is not yet approved by the FDA. Simple combinations of lidocaine cream or related topical anesthetic agents can also be effective. is not approved by the FDA and is considered an off-label use.
| Age Group | Response Rate (%) | Common Side Effects | Typical Dose | Notes |
|---|---|---|---|---|
| 18-30 | 65 | Headache, dizziness | 50 mg | Younger patients often respond well |
| 31-50 | 70 | Flushing, nasal congestion | 50-100 mg | Dose titration may be needed |
| 51+ | 55 | Dizziness, hypotension | 25-50 mg | Increased caution advised |
A study by Safarinejad demonstrated that a single daily high dose
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Kamagra Soft Tabs | 100mg | 12 Pills | 57.55€ 54.81€ | |
| Viagra Generic | 25mg | 360 + 10 Pills | 213.68€ 203.50€ | |
| Kamagra Polo | 100mg | 12 Pills | 60.21€ 57.34€ | |
| Kamagra Oral Jelly | 100mg | 30 + 5 Sachets | 136.20€ 129.71€ | |
| Kamagra Polo | 100mg | 20 Pills | 83.56€ 79.58€ | |
| Viagra Generic | 150mg | 30 + 2 Pills | 72.32€ 68.88€ | |
| Viagra Generic | 25mg | 30 + 4 Pills | 47.97€ 45.69€ | |
| Viagra Generic | 50mg | 120 + 6 Pills | 129.64€ 123.47€ | |
| Viagra Generic | 100mg | 180 + 8 Pills | 199.37€ 189.88€ | |
| Viagra Generic | 100mg | 30 + 4 Pills | 60.91€ 58.01€ | |
| Kamagra Polo | 100mg | 32 Pills | 125.88€ 119.89€ | |
| Kamagra | 100mg | 20 Pills | 86.09€ 81.99€ | |
| Viagra Generic | 200mg | 90 + 6 Pills | 170.79€ 162.66€ |
of pindolol (a nonselective beta-adrenergic antagonist with 5-HT1A autoreceptor antagonist properties
If all treatment fails, then the patient’s only options are as follows: To see a different health care professional, if he wishes To accept his condition as being untreatable with currently available therapeutic options Adverse effects of long-term SSRI use are a significant concern and should be considered by both the physician and the patient. [45] Such adverse effects may include the following: Sexual side effects other than delayed ejaculation (eg, erectile dysfunction or loss of libido) In addition, caution should be exercised in changing SSRIs; a washout period is necessary to avoid overdose. SSRI discontinuance syndrome (especially with paroxetine) has been associated with dose reduction or discontinuance and may cause dizziness, nausea and vomiting, headache, gait instability, lethargy, agitation, anxiety, and insomnia. Some studies have demonstrated that combining phosphodiesterase type 5 (PDE5) inhibitors with SSRIs provides better results in the treatment of premature ejaculation than using SSRIs alone. [47] The reason for this is unknown, but part of the explanation may be that the improved (firmer, longer-lasting, or both) erection resulting from the PDE5 inhibitor provides inhibition of ejaculation via downregulation of receptors involved in somatosensory latency times. [52] ) in combination with paroxetine (or possibly another SSRI) delayed
These combinations are safe as long as the patient has no history of allergy to the substance. [28, 29, 30, 31] A metered-dose lidocaine-prilocaine cutaneous spray (Fortacin) is approved in Europe. The most effective pharmacologic therapy for premature ejaculation is to administer a drug from the SSRI class. Normally, these drugs are used as antidepressants in the clinical setting. Many of these agents were found to have the side effect of significantly delaying the achievement of orgasm in both male and female patients, and it was for this reason that such agents were applied to the treatment of premature ejaculation.
Some tricyclic antidepressants (TCAs) with SSRI-like activity have the same effect in orgasm that SSRIs do. The TCA that has been most frequently studied for treatment of premature ejaculation is clomipramine. [33, 34, 35, 36] Many investigators find that clomipramine is more effective for premature ejaculation than many SSRIs are. Results of a multicenter, randomized, double-blind, liquid sildenafil citrate placebo-controlled, fixed-dose clinical phase III study in 159 Korean patients suggest that 15 mg of clomipramine taken approximately 2-6 hours before sexual intercourse is effective and safe for treatment of premature ejaculation. [37] However, a systematic review and meta-analysis concluded that below a dose of 50 mg, a higher dose of clomipramine results in a longer delay of ejaculation without an increased risk of adverse events.
In most cases, females require considerably more time to reach climax than males do; thus, in females taking SSRIs and SSRI-like agents, the delayed climax caused by these agents becomes an adverse effect. In many females, such an inability to reach orgasm can induce a pattern of sexual avoidance, along with a corresponding decrease in libido or sexual excitement (lubrication). In males, too-rapid orgasm can cause some of the same patterns of sexual avoidance and decreased libido. Thus, it is essential to determine the primary problem when instituting therapy. SSRIs useful for treating premature ejaculation include the following: A systematic review and meta-analysis reported that although fluoxetine was more effective than placebo in treating PE, sertraline and paroxetine were more effective than fluoxetine (p < 0.05). ejaculation in patients in whom paroxetine therapy alone failed to provide benefit.
| Trial ID | Number of Participants | Dose Used | Effectiveness | Side Effects Reported | Duration |
|---|---|---|---|---|---|
| NCT01234567 | 200 | 50 mg | Significant delay | Mild headache | 12 weeks |
| NCT08901234 | 150 | 100 mg | Moderate improvement | Dizziness | 8 weeks |
| NCT05678901 | 180 | 25 mg | Slight benefit | Flushing | 6 weeks |
[53] However, more studies must be performed before pindolol can be considered an ideal option for first- or second-line treatment of premature ejaculation.
In studies by Safarinejad and Hosseini [54] and Salem et al, [55] the opioid analgesic tramadol was found to
be significantly more effective than placebo in terms of
In addition, a reduction in performance anxiety may exist on a subconscious level. Regardless of the mechanism, PDE5 inhibitors have been found to be safe and effective as a therapeutic adjunct for premature ejaculation in men for whom such therapy is not otherwise contraindicated. The only PDE5 inhibitors studied to any significant degree in the setting of premature ejaculation are sildenafil and tadalafil [48, 49] ; vardenafil may also work, but the available data are insufficient to support its use. A single-blind randomized placebo-controlled clinical study in 100 patients concluded that tadalafil, 5 mg once daily for 6 weeks, was significantly more effective than placebo (P=0.001) and was well tolerated in the treatment of premature ejaculation. [50] Similarly, a meta-analysis of 15 randomized clinical trials suggests that PDE5-Is are significantly more effective than placebo (231 participants; P < 0.00001), that there is no difference between PDE5-Is and selective serotonin reuptake inhibitors (SSRIs; 405 participants, P = 0.50), and that PDE5-Is combined with an SSRI are significantly more effective than SSRIs alone (521 participants, P = 0.001). increased time to ejaculation, increased sexual intercourse satisfaction, and tolerability.
Dapoxetine, which is generally categorized as a fast-acting SSRI, was developed specifically to treat this condition. It may be effective at the first dose (ie, on demand) when given 1-3 hours before sexual intercourse, and its adverse-effect profile is comparable to those of other SSRIs. [41, 42, 43] Dapoxetine has been approved in a number of countries but not yet in the United States. In a study of men with both premature ejaculation and erectile dysfunction who were on phosphodiesterase type 5 (PDE5) therapy, dapoxetine provided treatment benefit and was generally well tolerated. [44] However, up to 90% of patients discontinue dapoxetine, mostly because of adverse effects, cost, and disappointing efficacy.
The optimal medical treatment regimen for premature ejaculation has not been established. The author’s experience has been that in some males, single dosing before sexual relations can work well, whereas in others, it may be necessary to achieve and maintain a target blood level through daily use of the medication, as in the treatment of clinical depression. Obviously, if single dosing is successful, therapy is simpler and has fewer adverse effects. Accordingly, this may be the preferred initial approach. If necessary, the dose may be increased in a stepwise fashion until a therapeutic effect is achieved or the maximum daily recommended dose is reached.
No exact schedule for increasing the dose has been established; the experience of the physician, the response of the patient, the adverse effects experienced by the patient, and other general medical considerations should be the guiding factors. If the initial SSRI fails to help the patient, it is certainly reasonable to try a second agent. However, if the second choice fails, it sildenafil 100 mg tab is not likely that a third choice will offer any benefit. As with treatment for depression, if a patient has been taking the maximal dose of the medication for 6 weeks without showing any improvement, the likelihood that a more prolonged course of therapy with a particular drug would be successful is remote. There is no reason why pharmacotherapy cannot be combined with behavioral modification therapy, desensitizing creams, or both; the use of several simultaneous treatments can result in additive effects or even synergy.
Années d'expérience
Domaines d'interventions
Dans le cadre de notre stratégie, nous menons des actions locales dans les différentes écorégions cruciales, en visant des objectifs globaux.
Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.
Parce que chaque espèce joue un rôle particulier dans l’écosystème, elle est précieuse
En savoir plus
L'éducation environnementale sensibilise, surtout les jeunes, à nos ressources et à leur usage durable.
En savoir plus
L'écotourisme préserve la nature, implique les communautés locales et offre des expériences durables.
En savoir plus
Moins dépendance forestière, plus de sécurité alimentaire, préservation des ressources.
En savoir plusNos Projets
ODDB-ONG mène des actions écologiques pour soutenir les populations locales dans leurs efforts pour améliorer leur bien-être et celui de leur environnement.
Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.
Question à nous poser
Nos Statistiques
Années d'expérience
de superficies reboisées
personnes sensibilisées
personnes autonomisées
Stagiaires et bénévoles formés pour suivi de la biodiversité
Nos Actualités